Development of an assay to quantify tranexamic acid levels in plasma
Analytical Biochemistry · 2025
DOI: 10.1016/j.ab.2024.115714 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Biochemistry, 2025. Verfasst von Paul Y Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.…. Hauptthemen laut MEDLINE: Tranexamic Acid, Antifibrinolytic Agents, Fluorescence Resonance Energy Transfer. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Canadian Hemophilia Society, Margaret M. and Albert B. Alkek Department of Medicine, McMaster University.
Abstract (Originalsprache)
Dysregulations of blood clot breakdown (fibrinolysis) during vascular trauma can lead to excessive blood loss. Tranexamic acid (TXA) is an inhibitor of fibrinolysis that works by blocking the interaction between plasminogen and fibrin degradation products (FDPs) - a key step in fibrinolysis. Despite the widespread usage, there are no tests available in a clinical setting to monitor TXA levels. We developed a fluorescence resonance energy transfer (FRET)-based assay to quantify TXA concentrations in plasma by using 1) fluorescently labeled plasminogen, and 2) FDPs labeled with a fluorescence quencher. Once plasminogen binds the FDPs, the fluorescent signal is quenched. TXA causes plasminogen to dissociate from the FDPs, thus increasing fluorescence signal in a dose-dependent manner. The dose response was sensitive between 1 and 100 μM (0.16 and 15.7 mg/L). The intraassay and interassay variabilities were determined to be 5.7 % and 3.0 %, respectively. Limit of detection was estimated to be 0.28 μM (0.044 mg/L). When tested for measuring known levels of TXA added to plasma samples, the ratio between measured and expected TXA concentration was 1.0151. Our study demonstrates a novel assay that can rapidly quantify TXA concentrations in plasma samples, thus demonstrating its potential as an in-hospital tool.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada. Electronic address: paul.kim@taari.ca.
- Department of Biochemistry, McMaster University, Hamilton, Ontario, Canada.
- Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada.
- Thrombosis and Atherosclerosis Research Institute, Hamilton, Ontario, Canada; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Förderung
- Canadian Hemophilia Society
- Margaret M. and Albert B. Alkek Department of Medicine
- McMaster University
Zitieren
APA
Kim, P. Y., Vong, M., Lee, D., & Wu, C. (2025). Development of an assay to quantify tranexamic acid levels in plasma. Analytical Biochemistry. https://doi.org/10.1016/j.ab.2024.115714
Vancouver
Kim PY, Vong M, Lee D, Wu C. Development of an assay to quantify tranexamic acid levels in plasma. Analytical Biochemistry. 2025. doi:10.1016/j.ab.2024.115714
BibTeX
@article{Kim2025,
author = {Kim, Paul Y and Vong, Michelle and Lee, Dani and Wu, Chengliang},
title = {Development of an assay to quantify tranexamic acid levels in plasma},
journal = {Analytical Biochemistry},
year = {2025},
doi = {10.1016/j.ab.2024.115714}
}
EUVIMED